tiprankstipranks
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
US Market

Alnylam Pharma (ALNY) Income Statement

Compare
1,201 Followers

Alnylam Pharma Income Statement

Last quarter (Q4 2024), Alnylam Pharma's total revenue was $593.17M, an increase of 34.90% from the same quarter last year. In Q4, Alnylam Pharma's net income was $-83.76M. See Alnylam Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 2.25B$ 1.83B$ 1.04B$ 844.29M$ 492.85M
Gross Profit
$ 1.92B$ 1.52B$ 868.60M$ 704.14M$ 414.80M
Operating Expenses
$ 2.10B$ 1.80B$ 1.65B$ 1.41B$ 1.24B
Depreciation and Amortization
$ 56.67M$ 54.05M$ 44.47M$ 47.57M$ 34.77M
EBITDA
$ -178.85M$ -258.24M$ -926.56M$ -661.56M$ -736.33M
Operating Income
$ -176.88M$ -282.18M$ -785.07M$ -708.65M$ -828.44M
Other Income/Expenses
$ -2.05M$ -151.34M$ -341.92M$ -143.49M$ -27.16M
Pretax Income
$ -178.94M$ -433.52M$ -1.13B$ -852.14M$ -855.60M
Net Income
$ -278.16M$ -440.24M$ -1.13B$ -852.82M$ -858.28M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -2.16$ -3.52$ -9.30$ -7.20$ -7.46
Diluted EPS
$ -2.16$ -3.52$ -9.30$ -7.20$ -7.46
Weighted Average Shares Outstanding
128.59M 124.91M 121.69M 118.45M 114.99M
Weighted Average Shares Outstanding (Diluted)
128.59M 124.91M 121.69M 118.45M 114.99M
Currency in USD

Alnylam Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis